Publications by authors named "S Amatayakul-Chantler"
Article Synopsis
- Ongoing research is essential for tracking and understanding the emergence of new SARS-CoV-2 variants, particularly as diagnostic testing declines in Australia during the COVID-19 pandemic.
- In 2023, collaborations with pathology and genomics teams allowed for the monitoring of SARS-CoV-2 variants in New South Wales through various methods, including viral culture and analysis of immune responses from a large pool of blood donations.
- Findings indicated that while existing antibodies generally neutralized many variants, specific mutations in emerging strains, particularly JN.1, suggested future challenges in controlling their spread due to enhanced transmissibility.
Article Synopsis
- The Omicron variant of COVID-19, which began in 2022, evolved from several lineages (BA.1, BA.2, BA.5) and developed mutations that help it evade neutralizing antibodies.
- Researchers evaluated the effectiveness of antibody responses by tracking over 420,000 U.S. plasma donors and studying blood samples from vaccinated and recovered individuals, along with testing clinically approved therapies.
- Findings indicated that antibody responses improved over time, but emerging variants like BQ.1.1 and XBF were increasingly resistant to treatments like Evusheld and Sotrovimab, suggesting that even dominant variants can evade antibodies while maintaining a persistent advantage in spreading.
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
EBioMedicine
October 2022
Background: Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. The introduction of global vaccine programs has contributed to lower COVID-19 hospitalisation and mortality rates, particularly in developed countries. In late 2021, Omicron BA.
View Article and Find Full Text PDFGenetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using primary remnant diagnostic swabs. This, combined with quarantine testing and genomics surveillance, enabled the rapid isolation and characterization of all major SARS-CoV-2 variants circulating in Australia in 2021.
View Article and Find Full Text PDFBackground: Suppression of cyclic activity in cattle is often desired in alpine farming and for feedlot cattle, not intended for breeding. A cattle specific anti-GnRF vaccine (Bopriva™) is registered for use in heifers and bulls in different countries. In adult cows vaccinated with Bopriva™, the median period until recurrence of class III follicles was 78 days from the day of the 2nd vaccination and reversibility could be proven, as out of 11 experimental cows 10 cows became pregnant at first, and one cow at second insemination.
View Article and Find Full Text PDF